List of Excipients in Branded Drug TOBRADEX ST

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	TOBRADEX ST	tobramycin / dexamethasone	0065-0652	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	TOBRADEX ST	tobramycin / dexamethasone	0065-0652	EDETATE DISODIUM
Alcon Laboratories Inc	TOBRADEX ST	tobramycin / dexamethasone	0065-0652	HYDROCHLORIC ACID
Alcon Laboratories Inc	TOBRADEX ST	tobramycin / dexamethasone	0065-0652	PROPYLENE GLYCOL
Alcon Laboratories Inc	TOBRADEX ST	tobramycin / dexamethasone	0065-0652	SODIUM CHLORIDE

TOBRADEX ST Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 24, 2026

TOBRADEX ST is a preserved ophthalmic suspension containing tobramycin 0.3% and dexamethasone 0.05%. Its commercial differentiation depends less on the well-established active ingredients than on suspension quality, ocular residence time, dose uniformity, preservative performance, tolerability, and post-operative usability. The main opportunity for competitors is a preservative-free or improved multidose formulation that matches the product’s clinical performance while reducing ocular-surface liabilities.

What is TOBRADEX ST and how does it work?

TOBRADEX ST is an ophthalmic combination product marketed by Alcon. It combines:

Component	Function
Tobramycin 0.3%	Aminoglycoside antibacterial
Dexamethasone 0.05%	Corticosteroid anti-inflammatory
Hypromellose	Viscosity modifier and residence-time enhancer
Tyloxapol	Nonionic surfactant and wetting/dispersing aid
Sodium chloride and sodium sulfate	Tonicity and formulation-control agents
Boric acid	Buffering and tonicity contribution
Benzalkonium chloride 0.01%	Multidose preservative
Sodium hydroxide and sulfuric acid	pH adjustment
Purified water	Vehicle

The product is indicated for steroid-responsive inflammatory ocular conditions in which bacterial infection exists or is a risk. The label requires shaking before use because TOBRADEX ST remains a suspension rather than a true solution. The recommended dosing is generally one or two drops every four to six hours, with more frequent administration during the first 24 to 48 hours in severe disease (U.S. Food and Drug Administration [FDA], n.d.-a).

What excipients protect the TOBRADEX ST formulation?

TOBRADEX ST’s excipient system is designed to control four technical risks: sedimentation, poor redispersion, nonuniform dosing, and inadequate ocular residence.

Hypromellose

Hypromellose increases vehicle viscosity and slows gravitational settling of suspended active particles. It can improve ocular retention compared with a low-viscosity aqueous vehicle, potentially reducing immediate drainage through the nasolacrimal system.

Its commercial value is functional rather than proprietary. Hypromellose is widely used in ophthalmic products, so a competitor is unlikely to obtain broad protection merely from using the excipient. Protectable distinctions may arise from:

• A defined viscosity range at a specified shear rate
• A narrow hypromellose molecular-weight or substitution profile
• Particle-size distribution combined with polymer concentration
• Improved redispersion after storage
• Dose uniformity after defined periods of settling
• Compatibility with a preservative-free container

The key risk is excessive viscosity. A vehicle that is too viscous can impair drop formation, increase blur, create a sticky ocular sensation, or complicate filling and dispensing.

Tyloxapol

Tyloxapol is a nonionic surfactant used to wet hydrophobic drug particles and improve dispersion. In a suspension containing micronized dexamethasone and tobramycin-related solid material, wetting control can affect sedimentation, agglomeration, resuspendability, and delivered dose.

Tyloxapol also provides a formulation design point that can be tested against alternative surfactants, including polysorbates, poloxamers, or other ophthalmically acceptable wetting agents. A competitor using a different surfactant may avoid a narrow composition claim while preserving the same technical function.

Potential formulation claims could focus on:

1. Surfactant concentration relative to total suspended solids.
2. Particle-wetting performance after accelerated storage.
3. Absence of visible agglomeration.
4. Redispersion after a defined number of inversions.
5. Dose uniformity across the first, middle, and final doses.

Benzalkonium chloride

Benzalkonium chloride, or BAK, supports multidose sterility after opening. Its presence creates a commercial vulnerability because repeated exposure to BAK can be associated with ocular-surface irritation and epithelial toxicity, particularly in patients with chronic or frequent topical treatment (Baudouin et al., 2010).

The preservative is also a formulation constraint. Surfactants and polymers can alter preservative availability through micelle formation, adsorption, or binding. A product may pass a preservative-effectiveness test while still having an unfavorable ocular-surface profile.

The strongest commercial opportunity is a preservative-free TOBRADEX ST equivalent in unit-dose containers or a validated preservative-free multidose device. That opportunity would require control of microbial ingress through packaging rather than reliance on BAK.

How does TOBRADEX ST’s excipient strategy compare with competing ophthalmic products?

TOBRADEX ST competes with three product groups: other tobramycin/dexamethasone products, tobramycin monotherapy, and alternative steroid-antibiotic combinations.

Product category	Main formulation issue	Commercial positioning
TOBRADEX ST	Preserved suspension with viscosity and wetting aids	Branded combination, post-operative and inflammatory infection-risk use
Generic tobramycin/dexamethasone suspension	Must demonstrate pharmaceutical equivalence and bioequivalence pathway compliance	Lower price, substitution opportunity
Tobramycin solution	Easier dosing and no suspension-shaking issue	Antibacterial use without steroid
Tobramycin/dexamethasone ointment	Longer residence time but more blur and handling burden	Nighttime or selected post-operative use
Difluprednate products	Potent steroid positioning, different formulation and safety profile	Steroid-focused competition
Moxifloxacin/steroid combinations	Fluoroquinolone-based antibacterial strategy	Alternative post-operative prescribing

The critical comparison is not simply active-ingredient identity. A generic suspension must match the reference product’s dosage form, strength, route, active ingredients, and performance characteristics. Suspension products can present greater development complexity than solutions because particle size, polymorphism, sedimentation, redispersion, viscosity, and dose uniformity all affect performance.

What formulation patents could protect a TOBRADEX ST follow-on?

A follow-on developer is unlikely to secure broad exclusivity around tobramycin, dexamethasone, hypromellose, or BAK individually. Those materials are established pharmaceutical ingredients. More commercially relevant claims would protect the combination of attributes that produces a measurable performance advantage.

High-value formulation claim areas

Claim area	Potential commercial value	Design-around difficulty
Preservative-free multidose suspension	High	High
Defined viscosity and redispersion profile	Medium to high	Medium
Narrow particle-size distribution	Medium	Medium
Improved dose uniformity after storage	High	Medium
Reduced BAK concentration with validated preservation	Medium	Medium
Alternative surfactant system	Medium	Low to medium
In situ gelling vehicle	High	Medium to high
Extended ocular residence formulation	High	High
Dual-chamber or reconstitutable device	Medium	High
Packaging that limits microbial ingress	High	High

The strongest patent estate would combine composition claims, process claims, device claims, and performance-based claims. A single concentration claim would be easier to design around.

Manufacturing and process protection

Manufacturing know-how may be as important as issued composition patents. Relevant process variables include:

• Milling or homogenization of suspended drug particles
• Order of excipient addition
• Surfactant pre-wetting
• Polymer hydration time
• Mixing shear and temperature
• Deaeration before filling
• Sterilization or aseptic processing
• Filling accuracy for low-volume ophthalmic containers
• Container-closure integrity

A formulation that performs well at laboratory scale may fail during commercial manufacture because viscosity, particle distribution, and sedimentation change with vessel geometry and shear history. Process patents and confidential manufacturing controls can create barriers even where the composition is readily understood.

What is the FDA regulatory status of TOBRADEX ST?

TOBRADEX ST is an FDA-approved prescription ophthalmic product regulated as a new drug application product. The FDA-approved label identifies it as a sterile ophthalmic suspension containing tobramycin and dexamethasone (FDA, n.d.-a).

Key regulatory characteristics include:

Regulatory feature	TOBRADEX ST position
Dosage form	Ophthalmic suspension
Route	Topical ophthalmic
Active ingredients	Tobramycin and dexamethasone
Strength	0.3% and 0.05%
Prescription status	Prescription drug
Product type	Combination antibiotic-corticosteroid
Preservative	Benzalkonium chloride
Administration issue	Must be shaken before use
Primary regulatory challenge for generics	Suspension equivalence and product-performance matching

A generic applicant would generally pursue an ANDA if the product can meet the applicable pharmaceutical equivalence, bioequivalence, quality, labeling, and other requirements. A differentiated product with a new preservative system, device, delivery profile, or clinical use may require a 505(b)(2) strategy rather than a conventional ANDA (FDA, 2023).

What is the Orange Book and patent status of TOBRADEX ST?

The Orange Book identifies FDA-approved drug products and, where applicable, listed patents and regulatory exclusivity. Patent conclusions should be based on the current product entry, patent-listing status, and relevant court or FDA records rather than on the product label alone (FDA, n.d.-b).

For TOBRADEX ST, the principal commercial IP questions are:

1. Whether the reference product has active FDA-listed patents.
2. Whether any listed patent covers the formulation, method of use, or delivery system.
3. Whether a generic applicant must file a Paragraph IV certification.
4. Whether pediatric or other regulatory exclusivity remains active.
5. Whether non-Orange-Book patents, trademarks, trade dress, or device rights affect launch risk.

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. If the reference sponsor brings suit within the statutory period, FDA approval of the ANDA may be stayed for up to 30 months, subject to statutory exceptions and court developments (FDA, 2023).

The practical IP risk is likely to be narrower than for a patented small-molecule active ingredient. The active ingredients are old and widely used. Commercial protection is more likely to depend on formulation differentiation, brand recognition, manufacturing quality, customer relationships, and any surviving listed patent or regulatory exclusivity.

When does TOBRADEX ST lose exclusivity?

TOBRADEX ST’s active-ingredient exclusivity is not the principal barrier to competition because tobramycin and dexamethasone are established compounds. The relevant loss-of-exclusivity analysis must separate:

• Active-ingredient patent expiry
• Combination-product patents
• Formulation patents
• Method-of-use patents
• FDA regulatory exclusivity
• Trademark protection
• ANDA approval timing
• Litigation-related stays

No reliable commercial conclusion follows from the product’s original approval date alone. FDA approval does not automatically establish a long remaining exclusivity period, and the absence of a visible composition patent does not eliminate non-Orange-Book formulation or device rights.

For forecasting, a generic launch model should use three scenarios:

Scenario	Entry condition	Commercial effect
Low-risk entry	No blocking patent or litigation delay	Rapid price erosion after approval
Litigation-delayed entry	Paragraph IV suit and statutory stay	Delayed approval and possible settlement
Differentiated entry	Preservative-free or device-based product	Premium pricing with limited automatic substitution

Which companies are challenging or competing with TOBRADEX ST?

The most direct competitors are generic manufacturers with approved or pending tobramycin/dexamethasone ophthalmic products. The competitive field can include:

• Generic ophthalmic manufacturers
• Branded ophthalmology companies
• Contract development and manufacturing organizations
• Device companies supplying preservative-free multidose systems
• Specialty pharmaceutical companies using 505(b)(2) pathways

A company does not need to copy the TOBRADEX ST excipient system to compete. It can target a specific weakness:

• No shaking requirement
• Preservative-free dosing
• Lower ocular-surface toxicity
• Better post-operative adherence
• Longer dosing intervals
• Lower unit cost
• Improved drop-size control
• Better performance in pediatric or sensitive-eye populations

The strongest competitor may therefore be a product with the same active ingredients but a materially different delivery system.

What commercial opportunities exist for TOBRADEX ST excipients?

Preservative-free unit-dose suspension

A unit-dose product would eliminate BAK exposure and could command a premium in post-operative ophthalmology, dry-eye populations, and patients requiring repeated courses. The tradeoff is higher packaging cost, more material consumption, and weaker convenience for patients using multiple daily doses.

Preservative-free multidose delivery

A nonpreserved multidose bottle with a microbial-barrier valve or one-way pump offers a larger commercial opportunity than unit-dose packaging. It preserves convenience while addressing BAK concerns. The main development burden is container-closure integrity, microbial ingress testing, extractables and leachables, dose consistency, and device usability.

Improved suspension technology

An optimized hypromellose-surfactant system could target:

• Faster redispersion
• Fewer required inversions
• More uniform dosing throughout bottle life
• Lower sedimentation rate
• Reduced particle agglomeration
• Lower viscosity during dispensing with higher residence after instillation

These performance claims would need robust analytical methods and stability data.

Alternative polymers and in situ gels

Poloxamers, carbomers, cellulose derivatives, and other ophthalmically accepted polymers could create temperature- or shear-responsive systems. A successful formulation could increase residence time without causing excessive blur or discomfort.

Device-led differentiation

Drop-size reduction can materially improve bottle life and reduce drug waste. A delivery system that dispenses a consistent small drop can reduce overflow, improve dosing precision, and support payer or institutional purchasing arguments.

What revenue exposure does TOBRADEX ST create?

Alcon does not generally report standalone global revenue for individual products in its public financial reporting. Product-level revenue exposure is therefore best evaluated through market share, prescription volume, formulary position, procedure volume, and pricing rather than a separately disclosed TOBRADEX ST revenue line (Alcon Inc., 2024).

The principal revenue risks are:

• Generic substitution after approval
• Price compression among ophthalmic suspensions
• Prescriber movement toward fluoroquinolone-steroid combinations
• BAK concerns in repeat users
• Reduced use of combination products because of antimicrobial-stewardship policies
• Hospital and ambulatory-surgery-center purchasing pressure

The principal growth opportunities are:

• Premium preservative-free formulations
• Ophthalmic surgery channel partnerships
• Contract manufacturing of sterile suspension products
• Regional licensing of formulation or device technology
• Lifecycle management through new packaging
• 505(b)(2) products with differentiated residence time or dosing

How strong is the TOBRADEX ST patent estate?

The commercial strength of the estate depends on current listed patents, remaining terms, claim scope, and enforceability. The underlying active ingredients provide limited strategic defensibility because they are established. A stronger estate would require claims directed to a specific suspension architecture, preservative-free delivery platform, manufacturing process, or validated performance profile.

A practical strength assessment is:

Asset	Likely strength
Tobramycin composition claims	Low for new market entry
Dexamethasone composition claims	Low for new market entry
Broad active-ingredient combination claims	Low to medium
Narrow excipient-ratio claims	Medium
Preservative-free multidose device claims	Medium to high
Manufacturing process claims	Medium, if difficult to detect or reproduce
Method-of-use claims	Variable and indication-dependent
Trademark and brand protection	High for branding, low against true generic substitution
Trade secrets	Potentially high if process-sensitive

Key Takeaways

• TOBRADEX ST’s differentiation is primarily formulation-based, not active-ingredient-based.
• Hypromellose supports viscosity and ocular residence; tyloxapol supports particle wetting and suspension quality.
• BAK is both a functional preservative and a commercial vulnerability.
• The most attractive follow-on opportunity is a preservative-free multidose suspension with equivalent dose uniformity and sterility performance.
• Generic entry risk depends on current FDA Orange Book listings, Paragraph IV certifications, litigation, and ANDA approval timing.
• Formulation, device, manufacturing, and performance claims offer more defensible IP positions than broad claims to tobramycin or dexamethasone.
• Product-level TOBRADEX ST revenue is not separately disclosed by Alcon, so market exposure must be modeled using channel and prescription data.
• A 505(b)(2) product could support premium positioning if it provides meaningful improvements in preservation, residence time, dosing, or usability.

FAQs

Can hypromellose alone create a strong patent position for a TOBRADEX ST competitor?

Usually not. Hypromellose is a well-established ophthalmic excipient. Patent value would come from a defined concentration, polymer grade, viscosity profile, particle system, or measurable performance result that is difficult to reproduce without practicing the claim.

Is a preservative-free TOBRADEX ST product automatically substitutable for the branded product?

No. Preservative status, packaging, formulation performance, labeling, and regulatory pathway determine substitutability. A preservative-free product may require a different regulatory strategy and may not qualify for automatic pharmacy substitution solely because it contains the same active ingredients.

What is the biggest technical risk in developing a generic TOBRADEX ST suspension?

The principal risk is maintaining dose uniformity throughout the bottle life. Sedimentation, caking, agglomeration, poor redispersion, and variable drop delivery can create quality and equivalence problems.

Can a device patent block a generic ophthalmic suspension?

Yes. A device patent may affect a multidose container, valve, pump, microbial-barrier system, or drop-dispensing mechanism. Device claims can remain commercially relevant even when active-ingredient patents have expired.

Is a 505(b)(2) strategy preferable to an ANDA for a new TOBRADEX ST formulation?

A 505(b)(2) strategy is more relevant when the product changes the vehicle, preservative system, device, dosing profile, or clinical positioning in a way that cannot be fully supported through an ANDA equivalence pathway. An ANDA is generally more efficient where the product closely matches the reference suspension.

References

1. Alcon Inc. (2024). Annual report for the fiscal year ended December 31, 2023.
2. Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334.
3. U.S. Food and Drug Administration. (2023). ANDA submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (n.d.-a). TOBRADEX ST: Tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.05% prescribing information.
5. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.